Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)

Simply Wall St.01-17

With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s (NASDAQ:CADL) future prospects. Candel Therapeutics, Inc., a clinical stage ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604859940?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-17 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604859940","market":"us","top_or_hot":-1,"title":"Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)","media":"Simply Wall St.","content":"<div>\n<p>With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s (NASDAQ:CADL) future prospects.  Candel Therapeutics, Inc., a clinical stage ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/breakeven-on-the-horizon-for-candel-therapeutics-inc-nasdaqc\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBreakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-17 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/breakeven-on-the-horizon-for-candel-therapeutics-inc-nasdaqc><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s (NASDAQ:CADL) future prospects.  Candel Therapeutics, Inc., a clinical stage ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/breakeven-on-the-horizon-for-candel-therapeutics-inc-nasdaqc\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USJW.SI","symbol_name":"ALPHAB 3xLongSG261006","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/breakeven-on-the-horizon-for-candel-therapeutics-inc-nasdaqc","article_id":"2604859940","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cadl/candel-therapeutics/news/breakeven-on-the-horizon-for-candel-therapeutics-inc-nasdaqc","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604859940","pubTimestamp":1768653773,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"USJW.SI":"ALPHAB 3xLongSG261006","QQQM":"NASDAQ100指数ETF-Invesco","PSQ":"做空纳斯达克100指数ETF-ProShares","TSYW.SI":"TESLA 3xLongSG261006","NVIW.SI":"NVDA 3xLongSG261006","BK4539":"次新股","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QYLD":"纳斯达克100 Covered Call ETF-Global X","USAW.SI":"AMZN 3xLongSG261006","QLD":"2倍做多纳斯达克100指数ETF-ProShares","BK4139":"生物科技","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","CADL":"Candel Therapeutics, Inc.",".IXIC":"NASDAQ Composite","QYLG":"Nasdaq 100 Covered Call & Growth ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","TQQQ":"纳指三倍做多ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","QQQJ":"Invesco NASDAQ Next Gen 100 ETF"},"translate_title":"Candel Therapeutics，Inc.（纳斯达克：CADL）即将实现盈亏平衡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QQQM":0.6,"USAW.SI":0.6,"PSQ":0.6,".IXIC":1.5,"QLD":0.6,"CADL":1.5,"QQQE":0.6,"QQQY":0.6,"QYLG":0.6,"TQQQ":0.6,"USJW.SI":0.6,"QYLD":0.6,"TSYW.SI":0.6,"QID":0.6,"NQmain":0.6,"NVIW.SI":0.6,"SQQQ":0.6,"GPIQ":0.6,"MNQmain":0.6,"QQQJ":0.6},"content_text":"With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s (NASDAQ:CADL) future prospects.  Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.    The US$326m market-cap company posted a loss in its most recent financial year of US$55m and a latest trailing-twelve-month loss of US$23m shrinking the gap between loss and breakeven.    The most pressing concern for investors is Candel Therapeutics' path to profitability – when will it breakeven?  Below we will provide a high-level summary of the industry analysts’ expectations for the company. Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit. Consensus from 6 of the American Biotechs analysts is that Candel Therapeutics is on the verge of breakeven.   They anticipate the company to incur a final loss in 2027, before generating positive profits of US$126m in 2028.   So, the company is predicted to breakeven approximately  2 years from today.    What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 58%,    which signals high confidence from analysts.  Should the business grow at a slower rate, it will become profitable at a later date than expected.  NasdaqGM:CADL Earnings Per Share Growth January 17th 2026 Given this is a high-level overview, we won’t go into details of Candel Therapeutics' upcoming projects,  however,  take into account  that typically   biotechs, depending on the stage of product development, have irregular periods of cash flow.   This means that a high growth rate is not unusual, especially if the company is currently in an investment period.    Check out our latest analysis for Candel Therapeutics  One thing we’d like to point out is that  The company has managed its capital judiciously,  with debt making up 6.5% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.    AdvertisementNext Steps: There are key fundamentals of Candel Therapeutics which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Candel Therapeutics, take a look at Candel Therapeutics' company page on Simply Wall St. We've also compiled a list of  pertinent  aspects  you should further examine:  Valuation: What is Candel Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Candel Therapeutics is currently mispriced by the market.Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Candel Therapeutics’s board and the CEO’s background.Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604859940","isCrawlerRequest":true}